Summary & Overview
HCPCS J0491: Injection, anifrolumab-fnia, 1 mg
HCPCS Level II code J0491 denotes the billed drug product anifrolumab-fnia at a unit of 1 mg. As a HCPCS code for a biologic injection, it matters nationally because it is the standardized identifier used by payers and providers for claims, coverage determinations, and payment processing for this specialty therapeutic. Accurate coding of biologic units affects patient cost-sharing, utilization tracking, and pharmacy/medical benefit delineation.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J0491 represents clinically and operationally, common sites where the product is delivered, and the typical considerations payers apply when adjudicating claims for unit-priced biologic HCPCS codes. The publication outlines benchmarks and payment context, summarizes any relevant policy updates impacting coverage and billing workflows, and provides clinical context for where anifrolumab-fnia is used.
This summary is intended for national audiences involved in coding, billing, revenue cycle management, and payer policy. Data not provided in the input (such as associated taxonomies, specific ICD-10 pairings, and payer-specific fee schedules) is explicitly noted as unavailable where relevant in the full publication.
Billing Code Overview
HCPCS Level II code J0491 represents the medication product anifrolumab-fnia, billed per milligram as "Injection, anifrolumab-fnia, 1 mg". This code is used to report administration of the biologic agent itself rather than the administration procedure.
Service Type: Drug administration — parenteral/biologic product
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or physician office where biologic injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 42-year-old woman with moderate-to-severe systemic lupus erythematosus (SLE) refractory to standard therapies presents to an outpatient infusion center for administration of biologic therapy. The provider orders J0491 (anifrolumab-fnia) dosed per weight/standard dosing regimen. The clinical workflow includes verification of indication and prior authorization, baseline laboratory assessment (including CBC, CMP, and screening for active infection), informed consent, and review of allergy history. On day of service the patient is registered, vital signs recorded, and IV access obtained. The clinician administers the prescribed dose of J0491 by intravenous infusion per product-specific infusion rate and monitoring guidelines. The patient is observed in the infusion chair for infusion-related reactions and post-infusion vitals are recorded. Documentation includes drug name and NDC, dosage in milligrams, lot number, route, start and stop times, administration site, and any reactions. Billing uses HCPCS Level II code J0491 reported per milligram administered with appropriate modifier(s) if applicable (for example, JW for discarded wastage). Typical sites of service are outpatient infusion centers, specialty infusion clinics, hospital outpatient departments, and oncology/rheumatology infusion suites.
Coding Specifications
| Modifier | Description | When to Use |
|---|